An extraordinary general meeting of Cell Impact AB (Nasdaq First North GM: CI B) was held on August 9, 2021.
Due to the Covid-19 pandemic, the extraordinary general meeting was conducted by postal vote, without physical attendance.
Authorization for the board of directors to resolve upon issue of shares, warrants and/or convertibles
The extraordinary general meeting authorized the board to, until the next annual general meeting and within the limits of the articles of association and on one or more occasions and with or without deviation from the shareholders’ preferential rights, resolve upon issues of shares, warrants, and/or convertibles, provided that such issues may not entail an increase of the company’s share capital by more than 20 percent, calculated on the size of the share capital the first time the authorization is used.
Issues may be made against cash payment, issue in kind and/or set-off, or otherwise be combined with conditions. Issues shall be made in order to increase the production capacity and prepare the organization to enable future growth. Should the board of directors resolve on an issue of shares with deviation from the shareholders’ preferential rights, the issue of share shall be made at market terms and conditions.
For more detailed information on the content of the resolutions, please see the notice convening the extraordinary general meeting and the complete proposals, which are available on the company’s website www.cellimpact.com.